NCT03734653View on ClinicalTrials.gov

Testosterone Therapy in Castration Resistant Prostate Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 18, 2019

Primary Completion Date

August 14, 2024

Study Completion Date

August 31, 2025

Conditions
Prostate CancerCastration-Resistant Prostate Cancer
Interventions
DRUG

Transdermal Testosterone

Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.

DRUG

Standard of Care, Enzalutamide

Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.

Trial Locations (1)

80045

University of Colorado Hospital, Aurora

All Listed Sponsors
collaborator

Cancer League of Colorado

OTHER

lead

University of Colorado, Denver

OTHER